Sort
82,697 grants matching “vaccine development”
LINKING ANTIGENIC & GENETIC VARIATION OF DENGUE TO INDIVIDUAL AND POPULATION RISK
$755,921Derek A Cummings · University Of Florida · R01 · FY2016 · AI
Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection
$755,894Jarrod Mousa · University Of Georgia · R01 · FY2023 · AI
Potent broadly neutralizing antibody development against the HIV-1 fusion peptide epitope
$755,855Brandon James Dekosky · Massachusetts General Hospital · R01 · FY2025 · AI
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$755,852Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Structure-based design of broad flavivirus immunogens
$755,795Jonathan R. Lai · Albert Einstein College Of Medicine · R01 · FY2021 · AI
Development of the neonatal mucosal immune system in nonhuman primates
$755,770Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2015 · AI
Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus
$755,681Kevin L Legge · University Of Iowa · R01 · FY2024 · AI
CCR5-mutant monkey model to facilitate the development of novel stem cell-based therapies for AIDS
$755,670Igor I Slukvin · University Of Wisconsin-Madison · R24 · FY2017 · OD
Administrative Core
$755,576Dennis L. Kasper · Harvard Medical School · U54 · FY2011 · AI
Applications of a robust, vector-free intracellular delivery platform for immune cells
$755,544Scott McNabb Loughhead · Sqz Biotechnologies Company, Inc. · R44 · FY2018 · GM
ADOLESCENT MEDICINE TRIALS NETWORK FOR HIV/AIDS
$755,526Children'S Research Institute · U01 · FY2004 · HD
Defining the impact of host factors on the molecular architecture and bacterial physiology of Staphylococcus aureus abscesses
$755,506James E Cassat · Vanderbilt University Medical Center · R01 · FY2021 · AI
Defending Against Systemic Mycoses
$755,466University Of Cincinnati · P01 · FY2004 · AI
Project 2: Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors
$755,463Scott G Hansen · Oregon Health & Science University · P01 · FY2022 · AI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
$755,448Christopher D Vanderwal · University Of California-Irvine · R01 · FY2018 · AI
Duration of Hormonal Contraceptive Use: Immune Responses & Vaginal Microbiota
$755,415Khalil G Ghanem · Johns Hopkins University · R01 · FY2014 · AI
Pre-clinical Commercialization of a Synthetically Designed, Live-attenuated RSV Vaccine
$755,377Steffen Mueller · Codagenix, Inc. · R44 · FY2017 · AI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE
$755,339University Of New Mexico · U19 · FY2000 · AI
EdTech-HPV: A Community Approach using Education and Technology to Increase HPV Vaccination
$755,286Abraham Aragones · Sloan-Kettering Inst Can Research · R01 · FY2016 · MD
Development of 2C inhibitors as broad-spectrum enterovirus antivirals
$755,280Jun Wang · Rutgers Biomedical And Health Sciences · R01 · FY2024 · AI
Rational design of a unique vaccine for emerging pandemic coronaviruses
$755,225Liang Qiao · Loyola University Chicago · R01 · FY2025 · AI
Miami Treatment and Prevention Clinical Trials Unit (CTU)
$755,151Margaret A Fischl · University Of Miami School Of Medicine · UM1 · FY2016 · AI
Human Immune Responses to Tumor Antigens for Cancer Vaccine Development
$755,122Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Bi-functional Polymer-Attached Inhibitors of Influenza Viruses
$755,104Jianzhu Chen · Massachusetts Institute Of Technology · U01 · FY2011 · AI
Control of Tsetse Fly Transmitted Diseases in Kenya
$755,001Serap Aksoy · Yale University · U01 · FY2015 · AI